Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease

This study is testing a combination of three drugs — orelabrutinib, lisaftoclax, and rituximab — as a first treatment for patients with high-risk mantle cell lymphoma (MCL), a type of blood cancer. All three drugs target different pathways cancer cells rely on to survive. **You may be eligible if...** - You are over 14 years old - You have a confirmed new diagnosis of mantle cell lymphoma and have not yet received any treatment - Your cancer is stage II–IV - Your lymphoma has at least one high-risk feature: a high MIPI score, rapidly dividing cells (Ki67 above 30%), a TP53 mutation, or the blastic or pleomorphic (aggressive) cell type **You may NOT be eligible if...** - You have already started any treatment for MCL - Your cancer lacks any high-risk features - You have significant organ dysfunction - You are pregnant or breastfeeding - You have an active serious infection Talk to your doctor to see if this trial is right for you.